血清miR-320、HMGB1对急性呼吸窘迫综合征患者临床预后的影响

Effects of Serum miR-320 and HMGB1 on Clinical Prognosis of Patients with Acute Respiratory Distress Syndrome

目的探讨血清miR-320、高迁移率族蛋白B1(HMGB1)对急性呼吸窘迫综合征(ARDS)患者临床预后的影响。方法选择2019年3月~2021年3月河南科技大学第一附属医院收治的86例ARDS患者作为研究对象,患者均在本院接受规范化治疗,记录患者28d内病死及存活情况作为预后观察指标,将病死患者纳入预后不良组,将存活患者纳入预后良好组;所有患者入院时均接受血清miR-320、HMGB1检测,询问并记录患者初始状况资料,分析血清miR-320、HMGB1水平对ARDS患者临床预后的影响。结果86例ARDS患者经治疗,28d病死28例(32.56%),存活58例(67.44%);预后不良组中性粒细胞百分比、miR-320、HMGB1水平高于预后良好组,差异有统计学意义(P<0.05);COX回归分析结果显示,血清miR-320、HMGB1过表达是ARDS患者预后不良的影响因素(P<0.05)。结论血清miR-320、HMGB1过表达对ARDS患者预后不良存在一定影响。

Objective To investigate the effects of serum miR-320 and high mobility group protein B1(HMGB1)on the clinical prognosis of patients with acute respiratory distress syndrome(ARDS).Methods Eighty-six patients with ARDS treated in the First Affiliated Hospital of Henan University of Science and Technology from March 2019 to March 2021 were selected as the research subjects.All patients received standardized treatment in our hospital.The death and survival of patients within 28 days were recorded as prognostic indicators.The patients who died were included in the poor prognosis group,and the patients who survived were included in the good prognosis group.All patients were tested for serum miR-320 and HMGB1 at admission.The initial status data of patients were inquired and recorded,and the effects of serum miR-320 and HMGB1 levels on the clinical prognosis of patients with ARDS were analyzed.Results In 86 patients with ARDS after treatment,28 cases(32.56%)died and 58 cases(67.44%)survived in 28 days.The percentage of neutrophils,the levels of miR-320 and HMGB1 in the poor prognosis group were higher than those in the good prognosis group,the differences were statistically significant(P<0.05).The results of COX regression analysis showed that the overexpression of serum miR-320 and HMGB1 were the influencing factors of poor prognosis in patients with ARDS(P<0.05).Conclusion The overexpression of serum miR-320 and HMGB1 has a certain impact on the poor prognosis of patients with ARDS.